Last reviewed · How we verify

NVP-1203-R1 and NVP-1203-R2

NVP Healthcare · Phase 1 active Small molecule

NVP-1203-R1 and NVP-1203-R2 is a Small molecule drug developed by NVP Healthcare. It is currently in Phase 1 development. Also known as: NVP-1203-R1(A) and NVP-1203-R2(E).

At a glance

Generic nameNVP-1203-R1 and NVP-1203-R2
Also known asNVP-1203-R1(A) and NVP-1203-R2(E)
SponsorNVP Healthcare
ModalitySmall molecule
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about NVP-1203-R1 and NVP-1203-R2

What is NVP-1203-R1 and NVP-1203-R2?

NVP-1203-R1 and NVP-1203-R2 is a Small molecule drug developed by NVP Healthcare.

Who makes NVP-1203-R1 and NVP-1203-R2?

NVP-1203-R1 and NVP-1203-R2 is developed by NVP Healthcare (see full NVP Healthcare pipeline at /company/nvp-healthcare).

Is NVP-1203-R1 and NVP-1203-R2 also known as anything else?

NVP-1203-R1 and NVP-1203-R2 is also known as NVP-1203-R1(A) and NVP-1203-R2(E).

What development phase is NVP-1203-R1 and NVP-1203-R2 in?

NVP-1203-R1 and NVP-1203-R2 is in Phase 1.

Related